Welcome to our dedicated page for Cardio Diagnostics Holdings SEC filings (Ticker: CDIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardio Diagnostics Holdings, Inc. filings document a Nasdaq-listed medical technology company with common stock under CDIO and redeemable warrants under CDIOW. The company identifies as an emerging growth company and reports formal disclosures tied to its precision cardiovascular medicine business, including clinical data, reimbursement progress, corporate updates, and strategic priorities furnished through Regulation FD materials.
Its SEC record also includes proxy and annual meeting disclosures covering stockholder voting matters, board and governance items, and meeting procedures. Material-event filings provide updates on corporate communications and security-holder actions, while proxy statements describe proposals submitted to holders of the company’s common stock.
Cardio Diagnostics Holdings, Inc. (CDIO) reported that senior management is using a new August 2026 investor presentation to brief existing and prospective investors. The company focuses on AI- and epigenetics-based blood tests for cardiovascular disease risk stratification (Epi+Gen CHD) and diagnosis (PrecisionCHD), supported by a proprietary multi-omics engine and a growing IP portfolio across multiple jurisdictions.
The presentation highlights large estimated U.S. market opportunities for these tests, a company-owned CLIA lab intended to lower costs and increase capacity, and progress toward reimbursement, including specific CPT PLA codes, a final CMS payment rate, and initial commercial coverage. It also outlines ongoing and planned clinical, economic, and utility studies, as well as U.S. and international commercialization efforts. The investor materials are furnished under Regulation FD and are not deemed filed or incorporated by reference into Securities Act filings.
Cardio Diagnostics Holdings develops AI‑driven blood tests for cardiovascular disease. For the quarter ended June 30, 2026, it generated revenue of $5,360 and incurred a net loss of $1,501,468, or $0.51 per share, on operating expenses of $1,503,507.
For the first six months of 2026, revenue was $8,040 with a net loss of $3,289,626. Cash was $5,586,697 at June 30, 2026, and stockholders’ equity totaled $7,426,283, against total liabilities of $499,780.
The company continues to fund operations primarily through equity, including $3,693,470 of net proceeds from at‑the‑market share sales in 2026. With 2,959,469 shares outstanding, management notes ongoing operating losses, modest revenue to date, and dependence on future capital raises and broader test adoption.
Cardio Diagnostics Holdings, Inc. plans a virtual annual stockholder meeting on September 18, 2026, where holders of 2,959,469 common shares as of July 31, 2026 can vote. Stockholders will elect seven directors, approve a new share-issuance authorization, and ratify Prager Metis CPA’s LLC as auditor for 2026.
The core item is the 2026 Issuance Proposal, which would permit, in one or more non-public transactions, the future sale of up to 5.0 million shares of common stock (or equivalents) for up to $10.0 million, at discounts up to 25% below market, within three months of approval (extendable to six months with Nasdaq consent), in compliance with Nasdaq Listing Rule 5635(d). If fully used, outstanding shares could rise to about 7,959,469, an increase of approximately 169%.
The company explains this authority is intended to provide an alternative capital-raising tool alongside its existing at-the-market facility, under which it has already raised about $18.75 million and issued 2,251,181 shares. The proxy discusses potential effects of any such financing, including dilution of existing ownership, possible share-price pressure, and anti-takeover implications, and outlines the board’s governance structure, committee composition, and emerging growth company status.
Cardio Diagnostics Holdings focuses on AI-driven, epigenetics-based blood tests to assess three-year coronary heart disease (CHD) event risk and detect CHD, built on its proprietary Multi-Omics Engine™. Key products include Epi+Gen CHD™ and PrecisionCHD™, both offered as laboratory-developed tests through a CLIA-certified high-complexity lab, plus the HeartRisk™ risk-intelligence software and CardioInnovate360™ RUO offering.
The company is commercializing through health systems, innovative providers, self-insured employers, high-income consumers and international partners, supported by CPT PLA reimbursement codes with a $854 CMS gapfill rate per test and an at-the-market equity program with Craig-Hallum that has raised several million dollars. It reports an extensive patent estate covering integrated genetic–epigenetic biomarkers for cardiovascular disease and diabetes, and estimates large addressable markets for its CHD tests within the growing global cardiovascular diagnostics sector.
Cardio Diagnostics Holdings, Inc. plans a virtual annual stockholders’ meeting on September 18, 2026, with holders of common stock at the close of business on July 31, 2026 entitled to vote. Stockholders will elect seven directors and consider auditor ratification.
The key item is a 2026 Issuance Proposal seeking advance approval under Nasdaq Marketplace Listing Rule 5635(d) to issue, in one or more non‑public financings, up to 5.0 million shares of common stock (or equivalents) for up to $10.0 million, at no more than a 25% discount to market, generally within three months of approval.
The company explains this would supplement its existing at‑the‑market program and help address capital needs while the share price is low. It notes that fully using this authority could increase shares outstanding by approximately 169% and be highly dilutive and potentially anti‑takeover. The board unanimously recommends voting FOR all three proposals.
Cardio Diagnostics Holdings, Inc. director Peter K. Fung received a grant of stock options as part of his compensation. On June 30, 2026, he was awarded 2,854 stock options with a conversion price of $2.19 per share, each option representing the right to buy one share of common stock. These are classified as a grant or award, not an open-market purchase or sale. Following this award, Fung holds a total of 12,367 stock options linked to Cardio Diagnostics common stock, giving him additional potential future ownership if he chooses to exercise the options before they expire in 2036.
Cardio Diagnostics Holdings, Inc. director Wendy J. Betts received a grant of stock options covering 2,854 shares of common stock. The options have an exercise price of $2.19 per share and expire on June 30, 2036. This is a compensation-related award, not an open-market trade, and brings her directly held option awards to a total of 12,367 underlying shares.
Cardio Diagnostics Holdings director James Intrater received a new stock option grant as part of his compensation. On June 30, 2026, he was granted options to acquire 2,854 shares of common stock at an exercise price of $2.19 per share, expiring on June 30, 2036. After this award, he directly holds options for 13,318 shares in total.
Cardio Diagnostics Holdings director Burton Paul Frederick received a grant of stock options, providing additional equity-based compensation. The award covers 2,854 options to buy Common Stock at an exercise price of $2.19 per share, expiring on June 30, 2036. Following this grant, Frederick holds 13,318 stock options directly.
Cardio Diagnostics Holdings, Inc. reported a first-quarter 2026 net loss of $1,788,158 on very early-stage revenue of $2,680, reflecting continued investment ahead of broad commercialization. Operating expenses were $1,787,517, driven mainly by general and administrative costs, sales and marketing, and research and development.
Cash increased to $7,077,021 as of March 31, 2026, helped by $3,693,470 in net proceeds from at-the-market common stock sales, leaving stockholders’ equity at $8,903,399. The company continues to expand adoption of its AI-driven cardiovascular tests, build evidence, and rely on equity financing while acknowledging its disclosure controls were not effective.